Familial nephrotic syndrome
MONDO:0002350An instance of nephrotic syndrome that is caused by an inherited modification of the individual's genome.
Also known as: congenital nephrotic syndrome, hereditary nephrotic syndrome
25 clinical trials for this condition and its sub-types, 0 tagged with Familial nephrotic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Familial nephrotic syndrome
-
Nephrotic syndrome 14 3 trials
-
Nephrotic syndrome, type 4 1 trial
-
1 sub-type
- Pierson syndrome 0 trials
-
14 sub-types
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 0 trials
- Familial steroid-resistant nephrotic syndrome with sensorineural deafness 0 trials
- Focal segmental glomerulosclerosis 1 0 trials
- Nephrotic syndrome, type 10 0 trials
- Nephrotic syndrome, type 11 0 trials
- Nephrotic syndrome, type 12 0 trials
- Nephrotic syndrome, type 13 0 trials
- Nephrotic syndrome, type 2 0 trials
- Nephrotic syndrome, type 3 0 trials
- Nephrotic syndrome, type 6 0 trials
- Nephrotic syndrome, type 8 0 trials
- Nephrotic syndrome, type 9 0 trials
-
Nephrotic syndrome 15 0 trials
-
Nephrotic syndrome 16 0 trials
-
Nephrotic syndrome, IIa 26 0 trials
-
Nephrotic syndrome, type 17 0 trials
-
Nephrotic syndrome, type 18 0 trials
-
Nephrotic syndrome, type 19 0 trials
-
Nephrotic syndrome, type 20 0 trials
-
Nephrotic syndrome, type 21 0 trials
-
Nephrotic syndrome, type 22 0 trials
-
Nephrotic syndrome, type 23 0 trials
-
Nephrotic syndrome, type 24 0 trials
-
Can a gene-silencing drug calm overactive complement in kidney disease?
Disease control Not yet recruitingThis phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…
Phase 2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…
Early phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC